Sareum Holdings plc announced the appointments of Michael Owen, PhD and Clive Birch as Non-Executive Directors. Dr. Owen currently serves on the boards of several public and private biotechnology companies in the UK, Europe and the USA, including Avacta Group plc, ReNeuron plc, GammaDelta Therapeutics and Zealand Pharma A/S. He is also the Chairman of Ossianix Inc. In addition, Dr. Owen is Chairman of ReNeuron's and Avacta's scientific advisory boards, an advisor to Abingworth LLP and was until recently an advisor to the CRT Pioneer Fund and Clive Birch is an Independent Non-Executive Director of Cambridge Innovation Capital plc, a Cambridge-based builder of technology and healthcare companies. He is a retired partner of PricewaterhouseCoopers where his role was that of an auditor and reporting accountant with an industry specialism in early stage technology and healthcare companies. He was also part of the teams involved in fund raising and listing those clients on various markets. Michael Owen, aged 67, has been a director of the following companies. Current directorships: Avacta Group plc, ReNeuron plc, GammaDelta Therapeutics Ltd, Ossianix Inc., Ossianix UK Ltd, Iskuda Therapeutics Ltd, Zealand Pharma A/S, The Club Cricket Organisation Ltd. Clive Birch, aged 65, has been a director of the following companies. Current directorships: Cambridge Innovation Capital plc, Pigeon Land Limited, Pigeon Land 2 Limited, Pigeon (Shelford) Limited, Pigeon (Uplands & Heigham) Limited and Chrib Ltd.